To ensure that we are providing the best and most current information to our members, NAMI monitors current research across the field of mental health. On this page, you can find up-to-date information from government organizations like the National Institute of Mental Health (NIMH), private institutions like the Stanley Center for Psychiatric Research, and academic and industry researchers.
For more new stories from the National Institute of Mental Health, please visit their Science News website.
For more new stories from Substance Abuse and Mental Health Services, please visit their Newsletter website.
Dec 02 2019
Every five years, the National Institute of Mental Health (NIMH) creates a Strategic Plan for Research. As the lead federal agency for research on mental illness, the NIMH is responsible for guiding and supporting research in basic, translational and clinical science. The Strategic Plan acts as a roadmap to establish their priorities, impacting millions of dollars invested in research grants. The NIMH released a draft of the 2020-2025 Strategic Plan for Research and welcomes comments from the community. To view the draft Strategic Plan, please visit the NIMH website.
Nov 30 2019
Super-frequent emergency department (ED) users, people with 18 or more visits per year, often have complex medical, mental health and social needs. However, most strategies used to reduce ED visits focus only on medical needs. To emphasize the importance of a broader perspective, researchers analyzed ED visit data from San Francisco County, CA. The county’s coordinated data system showed that 67% of super-frequent ED users also received mental health treatment, with an average of two psychiatric hospitalizations. These results demonstrate how coordinated data can allow health systems to see the true needs of their populations. To learn more, see the article in Health Affairs.
Nov 18 2019
Ketamine has been shown to relieve depressive symptoms within hours of a single intravenous (IV) treatment. To develop a new therapy based on ketamine, researchers must account for potential side effects — especially given the drug’s history of recreational misuse. A new report analyzing data from five clinical trials conducted at NIH over 13 years shows that common side effects of a single IV treatment were mild and lasted only a few hours. This encouraging result supports ongoing research to develop practical, quick-acting antidepressants. To learn more, please visit the NIMH website.